Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

Table 2 Priority list of the OAIs

	A (2)	B (4)	C (3)	D (2)	E (1)	total
Amifampridine	6	12	9	6	3	36
Sodium phenylbutyrate^a	6	12	9	2	3	32
Pyridoxal phosphate^a	6	8	9	6	3	32
Chenodesoxycholic acid^a	2	12	9	6	3	30
Primaquine phosphate^a	2	12	9	6	3	30
Fenfluramine	2	12	6	6	3	29
Sodium hydroxybutyrate	2	12	3	6	3	26
Difencyprone	6	4	6	6	3	25
Bimyconase	2	8	6	2	1	19

Priority list of the OAIs based on five criteria with (A) the prevalence of the corresponding rare disease, (B) severity of the disease, (C) degree of available evidence, (D) price of the orphan active ingredient and (E) the ease of compounding. The weighing factor (which was multiplied with the score of the individual criterium) indicating the criteriums importance is mentioned between brackets. ^aOAIs included in current study

ISSN: 1750-1172